Dapivirine Ring: Phase III Results

Overview of results: Two large clinical trials — The Ring Study and ASPIRE — showed in 2016 that IPM's monthly vaginal ring containing the antiretroviral drug dapivirine can help reduce women's HIV-1 risk by approximately 30 percent overall and is safe for long-term use.

Greater HIV risk reduction associated with increased ring use: Participants who used the ring at least some of the time saw their HIV infection risk cut by 45 percent across both studies.

Next steps for the ring: IPM, the ring's developer, is pursuing approvals from global and national regulatory authorities to license the product in countries where women face the highest risk. 

Two open-label extension studies, DREAM and HOPE, are providing the ring to former Ring Study and ASPIRE participants, respectively. 

First-long-acting HIV prevention method: The dapivirine ring could be an important new self-initiated option for women, who bear the greatest burden of the global HIV/AIDS epidemic.

Impact: Modeling studies show that microbicides like the dapivirine ring would be cost-effective and have a significant public health impact as part of a broader toolkit that could avert tens of millions of HIV infections over time.

Learn more about the results from the Phase III dapivirine ring studies: